The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development
Open accessAbstract
Angiogenesis depends on specific molecular interactions between vascular cells and components of the extracellular matrix (ECM). This Perspective focuses on the functional role of integrins in angiogenesis and neovascularization. Specifically, we discuss the mechanism by which antagonists of αv integrins disrupt angiogenesis in vivo and how they may impact patients with cancer and inflammatory disease. Role of ECM and integrins during angiogenesis and vasculogenesis. Angiogenesis depends not only on growth factors and their receptors but is also influenced by receptors for ECM proteins. In general, cell adhesion to the ECM is mediated by integrins, heterodimeric transmembrane proteins that comprise a diverse family of over 15 α and 8 β subunits. Integrin subunits can heterodimerize in over 20 combinations. Different integrin combinations may recognize a single ECM ligand, while others bind several different ECM proteins. Integrin-mediated adhesion leads to intracellular signaling events that regulate cell survival, proliferation, and migration (1). These signals include elevation in intracellular pH and calcium, inositol lipid synthesis, and the tyrosine phosphorylation of a wide range of nonreceptor tyrosine kinases such as focal adhesion kinase and Src kinases, as well as adaptor proteins such as Shc, p130 CAS, and Crk II. These signaling events trigger a number of downstream signals, including activation of the Ras/mitogen-activated protein (MAP) kinase pathway (1).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Self-citationIntegrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Self-citationBrooks, P. C., Strömblad, S., Sanders, L. C., von Schalscha, T. L., Aimes, R. T., Stetler-Stevenson, W. G., Quigley, J. P., & Cheresh, D. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81235-0 · Cited by 1,552
Self-citationDefinition of Two Angiogenic Pathways by Distinct α v Integrins
Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., & Cheresh, D. A. (1995) · Science · doi:10.1126/science.270.5241.1500 · Cited by 1,321
Self-citationDetection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., & Li, K. C. P. (1998) · Nature Medicine · doi:10.1038/nm0598-623 · Cited by 850
Self-citationAplin, A. E., Howe, A., Alahari, S. K., & Juliano, R. L. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01359-0 · Cited by 847
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.
Brooks, P. C., Strömblad, S., Klemke, R., Visscher, D., Sarkar, F. H., & Cheresh, D. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118227 · Cited by 828
Self-citationHodivala-Dilke, K. M., McHugh, K. P., Tsakiris, D. A., Rayburn, H., Crowley, D., Ullman-Culleré, M., Ross, F. P., Coller, B. S., Teitelbaum, S., & Hynes, R. O. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5487 · Cited by 740
Embryonic mesodermal defects in α5 integrin-deficient mice
Yang, J. T., Rayburn, H., & Hynes, R. O. (1993) · Development · doi:10.1242/dev.119.4.1093 · Cited by 691
Bader, B. L., Rayburn, H., Crowley, D., & Hynes, R. O. (1998) · Cell · doi:10.1016/s0092-8674(00)81618-9 · Cited by 647
Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M., & Cheresh, D. A. (1998) · Cell · doi:10.1016/s0092-8674(00)80931-9 · Cited by 623
Self-citationEliceiri, B. P., Klemke, R., Strömblad, S., & Cheresh, D. A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.5.1255 · Cited by 396
Self-citationStrömblad, S., Becker, J. C., Yebra, M., Brooks, P. C., & Cheresh, D. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118808 · Cited by 383
Self-citationInvolvement of integrin alpha V gene expression in human melanoma tumorigenicity.
Felding-Habermann, B., Mueller, B. M., Romerdahl, C. A., & Cheresh, D. A. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115811 · Cited by 378
Self-citationHammes, H.-P., Brownlee, M., Jonczyk, A., Sutter, A., & Preissner, K. T. (1996) · Nature Medicine · doi:10.1038/nm0596-529 · Cited by 328
Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist
Storgard, C. M., Stupack, D. G., Jonczyk, A., Goodman, S. L., Fox, R. I., & Cheresh, D. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci3756 · Cited by 310
Self-citationDrake, C. J., Cheresh, D. A., & Little, C. D. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.7.2655 · Cited by 307
Self-citationEnenstein, J., & Kramer, R. H. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12395390 · Cited by 76
Cited by
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration
Rafii, S., & Lyden, D. (2003) · Nature Medicine · doi:10.1038/nm0603-702 · Cited by 1,577
Metadata
- Authors
- Eliceiri, B. P., & Cheresh, D. A.
- Venue
- Journal of Clinical Investigation
- Published
- 1999-05-01
- Volume
- 103
- Issue
- 9
- Pages
- 1227-1230
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2100363932
- Cited by
- 649
- References
- 18
- FWCI
- 21.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.